Matches in SemOpenAlex for { <https://semopenalex.org/work/W1726723198> ?p ?o ?g. }
Showing items 1 to 81 of
81
with 100 items per page.
- W1726723198 endingPage "1082" @default.
- W1726723198 startingPage "1077" @default.
- W1726723198 abstract "Background Pegylated interferon (PEG-IFN) alpha2b is currently used as a once weekly injection in combination with ribavirin for the treatment of chronic hepatitis C. Aim To test whether twice half-dose weekly administration may improve the virological response in difficult-to-treat hepatitis C virus-1 patients. Methods Thirty patients were treated with 1.5 μg/kg of PEG-IFN alpha2b given once weekly for 48 weeks (group A) and were compared with 30 patients treated with the same dose of PEG-IFN alpha2b divided in twice weekly doses of 0.75 μg/kg for the initial 4 weeks (group B). All patients were hepatitis C virus-1 positive and received weight-based ribavirin (800–1400 mg/daily). Results Weekly twice half-dose administration of PEG-IFN alpha2b for the first 4 weeks was associated with lower rates of biochemical and virological response at all time points compared with a once weekly schedule, and with significantly higher rates of in-therapy breakthrough leading to significantly lower rates of end of therapy response (week 48). The rate of sustained virological response was of 56.7% in group A and 36.7% in group B. Conclusions Weekly twice half-dose administration of PEG-IFN alpha2b is not superior to the standard once weekly schedule, and might be less efficacious." @default.
- W1726723198 created "2016-06-24" @default.
- W1726723198 creator A5005200492 @default.
- W1726723198 creator A5019459194 @default.
- W1726723198 creator A5022851801 @default.
- W1726723198 creator A5023873039 @default.
- W1726723198 creator A5037197403 @default.
- W1726723198 date "2007-07-25" @default.
- W1726723198 modified "2023-10-14" @default.
- W1726723198 title "Clinical trial: comparison of weekly once versus twice half-dose weekly administration of pegylated interferon alpha 2b in combination with ribavirin for the treatment of HCV-1 positive patients with chronic hepatitis C" @default.
- W1726723198 cites W1968972141 @default.
- W1726723198 cites W1988756262 @default.
- W1726723198 cites W2000104469 @default.
- W1726723198 cites W2003761258 @default.
- W1726723198 cites W2027545702 @default.
- W1726723198 cites W2030736973 @default.
- W1726723198 cites W2079634214 @default.
- W1726723198 cites W2114376411 @default.
- W1726723198 cites W2127685726 @default.
- W1726723198 cites W2163211052 @default.
- W1726723198 cites W2191643726 @default.
- W1726723198 doi "https://doi.org/10.1111/j.1365-2036.2007.03451.x" @default.
- W1726723198 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17877515" @default.
- W1726723198 hasPublicationYear "2007" @default.
- W1726723198 type Work @default.
- W1726723198 sameAs 1726723198 @default.
- W1726723198 citedByCount "3" @default.
- W1726723198 countsByYear W17267231982012 @default.
- W1726723198 crossrefType "journal-article" @default.
- W1726723198 hasAuthorship W1726723198A5005200492 @default.
- W1726723198 hasAuthorship W1726723198A5019459194 @default.
- W1726723198 hasAuthorship W1726723198A5022851801 @default.
- W1726723198 hasAuthorship W1726723198A5023873039 @default.
- W1726723198 hasAuthorship W1726723198A5037197403 @default.
- W1726723198 hasBestOaLocation W17267231981 @default.
- W1726723198 hasConcept C126322002 @default.
- W1726723198 hasConcept C203014093 @default.
- W1726723198 hasConcept C2522874641 @default.
- W1726723198 hasConcept C2776178377 @default.
- W1726723198 hasConcept C2776455275 @default.
- W1726723198 hasConcept C2776461080 @default.
- W1726723198 hasConcept C2776999253 @default.
- W1726723198 hasConcept C2780040827 @default.
- W1726723198 hasConcept C2909179924 @default.
- W1726723198 hasConcept C3020491458 @default.
- W1726723198 hasConcept C71924100 @default.
- W1726723198 hasConcept C90924648 @default.
- W1726723198 hasConceptScore W1726723198C126322002 @default.
- W1726723198 hasConceptScore W1726723198C203014093 @default.
- W1726723198 hasConceptScore W1726723198C2522874641 @default.
- W1726723198 hasConceptScore W1726723198C2776178377 @default.
- W1726723198 hasConceptScore W1726723198C2776455275 @default.
- W1726723198 hasConceptScore W1726723198C2776461080 @default.
- W1726723198 hasConceptScore W1726723198C2776999253 @default.
- W1726723198 hasConceptScore W1726723198C2780040827 @default.
- W1726723198 hasConceptScore W1726723198C2909179924 @default.
- W1726723198 hasConceptScore W1726723198C3020491458 @default.
- W1726723198 hasConceptScore W1726723198C71924100 @default.
- W1726723198 hasConceptScore W1726723198C90924648 @default.
- W1726723198 hasIssue "7" @default.
- W1726723198 hasLocation W17267231981 @default.
- W1726723198 hasLocation W17267231982 @default.
- W1726723198 hasOpenAccess W1726723198 @default.
- W1726723198 hasPrimaryLocation W17267231981 @default.
- W1726723198 hasRelatedWork W2000349119 @default.
- W1726723198 hasRelatedWork W2070127208 @default.
- W1726723198 hasRelatedWork W2076626959 @default.
- W1726723198 hasRelatedWork W2220604806 @default.
- W1726723198 hasRelatedWork W2278023447 @default.
- W1726723198 hasRelatedWork W2317554121 @default.
- W1726723198 hasRelatedWork W2408154710 @default.
- W1726723198 hasRelatedWork W2411773677 @default.
- W1726723198 hasRelatedWork W2461318346 @default.
- W1726723198 hasRelatedWork W246869748 @default.
- W1726723198 hasVolume "26" @default.
- W1726723198 isParatext "false" @default.
- W1726723198 isRetracted "false" @default.
- W1726723198 magId "1726723198" @default.
- W1726723198 workType "article" @default.